Literature DB >> 24066890

Innate immunity and vaccines.

Andrew Platt1, Lee Wetzler.   

Abstract

The use of vaccines has led to tremendous decreases in disease burdens across the world. Many challenges remain in expanding vaccine coverage to new pathogens, however, a struggle further hampered by a lack of understanding into many of the fundamental processes through which vaccines elicit robust immunity. In this review we cover recent advances in the field of innate immunity and vaccinology that offer new insights into the reasons some vaccines may succeed or fail. We begin with the secreted cytokines that can influence the nature of the adaptive immune response, and how these may be tuned with the use of particular adjuvants. From there we cover dendritic cells, perhaps the key cell at the interface between innate and adaptive immunity. We discuss mechanisms for targeting specific subsets of dendritic cells, and the effects of this targeting. We further discuss additional modifications of the vaccine formulation to enhance interactions with innate immunity, including phagocytocis and antigen presentation. Finally, we step back to review recent advances in systems biology, and the ability of these new tools to provide deeper understanding of innate immune functions. We hope that this review will provide researchers with access to a breadth and depth of recent work that will allow for the rational design of novel vaccines to combat the most serious infectious diseases of today and tomorrow.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24066890     DOI: 10.2174/15680266113136660185

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  10 in total

Review 1.  Role of Metallic Nanoparticles in Vaccinology: Implications for Infectious Disease Vaccine Development.

Authors:  Lázaro Moreira Marques Neto; André Kipnis; Ana Paula Junqueira-Kipnis
Journal:  Front Immunol       Date:  2017-03-08       Impact factor: 7.561

2.  Differences in B-Cell Immunophenotypes and Neutralizing Antibodies Against SARS-CoV-2 After Administration of BNT162b2 (Pfizer-BioNTech) Vaccine in Individuals with and without Prior COVID-19 - A Prospective Cohort Study.

Authors:  José Javier Morales-Núñez; Mariel García-Chagollán; José Francisco Muñoz-Valle; Saúl Alberto Díaz-Pérez; Paola Carolina Torres-Hernández; Saraí Citlalic Rodríguez-Reyes; Guillermo Santoscoy-Ascencio; José Julio Sierra García de Quevedo; Jorge Hernández-Bello
Journal:  J Inflamm Res       Date:  2022-08-04

Review 3.  Cancer immunotherapy with immunoadjuvants, nanoparticles, and checkpoint inhibitors: Recent progress and challenges in treatment and tracking response to immunotherapy.

Authors:  Michael-Joseph Gorbet; Ashish Ranjan
Journal:  Pharmacol Ther       Date:  2019-12-19       Impact factor: 12.310

4.  Citizen science initiative points at childhood BCG vaccination as a risk factor for COVID-19.

Authors:  José de la Fuente; Octavio Armas; Luis Sánchez-Rodríguez; Christian Gortázar; Alexander N Lukashev
Journal:  Transbound Emerg Dis       Date:  2021-04-20       Impact factor: 4.521

5.  DNA is an efficient booster of dendritic cell-based vaccine.

Authors:  Jinyao Li; Antonio Valentin; Rachel Kelly Beach; Candido Alicea; Barbara K Felber; George N Pavlakis
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

6.  The TLR2 Binding Neisserial Porin PorB Enhances Antigen Presenting Cell Trafficking and Cross-presentation.

Authors:  Michael L Reiser; Munir M Mosaheb; Christina Lisk; Andrew Platt; Lee M Wetzler
Journal:  Sci Rep       Date:  2017-04-07       Impact factor: 4.379

7.  Toll-Like Receptor Ligand-Based Vaccine Adjuvants Require Intact MyD88 Signaling in Antigen-Presenting Cells for Germinal Center Formation and Antibody Production.

Authors:  Munir M Mosaheb; Michael L Reiser; Lee M Wetzler
Journal:  Front Immunol       Date:  2017-03-03       Impact factor: 7.561

8.  Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines.

Authors:  Johannes Lutz; Sandra Lazzaro; Mohamed Habbeddine; Kim Ellen Schmidt; Patrick Baumhof; Barbara L Mui; Ying K Tam; Thomas D Madden; Michael J Hope; Regina Heidenreich; Mariola Fotin-Mleczek
Journal:  NPJ Vaccines       Date:  2017-10-19       Impact factor: 7.344

9.  A Vaccine Based on a Modified Vaccinia Virus Ankara Vector Expressing Zika Virus Structural Proteins Controls Zika Virus Replication in Mice.

Authors:  Patricia Pérez; María Q Marín; Adrián Lázaro-Frías; Nereida Jiménez de Oya; Ana-Belén Blázquez; Estela Escribano-Romero; Carlos Óscar S Sorzano; Javier Ortego; Juan-Carlos Saiz; Mariano Esteban; Miguel A Martín-Acebes; Juan García-Arriaza
Journal:  Sci Rep       Date:  2018-11-26       Impact factor: 4.379

10.  SARS-CoV-2 ferritin nanoparticle vaccine induces robust innate immune activity driving polyfunctional spike-specific T cell responses.

Authors:  Joshua M Carmen; Shikha Shrivastava; Zhongyan Lu; Alexander Anderson; Elaine B Morrison; Rajeshwer S Sankhala; Wei-Hung Chen; William C Chang; Jessica S Bolton; Gary R Matyas; Nelson L Michael; M Gordon Joyce; Kayvon Modjarrad; Jeffrey R Currier; Elke Bergmann-Leitner; Allison M W Malloy; Mangala Rao
Journal:  NPJ Vaccines       Date:  2021-12-13       Impact factor: 7.344

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.